These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38159033)

  • 1. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature.
    D'Oria O; Bogani G; Cuccu I; D'Auge TG; Di Donato V; Caserta D; Giannini A
    Expert Opin Pharmacother; 2024; 25(1):55-65. PubMed ID: 38159033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
    Mutlu L; Tymon-Rosario J; Harold J; Menderes G
    Expert Rev Anticancer Ther; 2022 Jun; 22(6):633-645. PubMed ID: 35533682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
    Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
    Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy for cervical cancer: current standard of care and new perspectives.
    Ketch PW; Zaharias RS; Leath CA
    Expert Opin Pharmacother; 2024 Aug; 25(12):1591-1603. PubMed ID: 39164924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab for the treatment of cervical cancer.
    Bizzarri N; Ghirardi V; Alessandri F; Venturini PL; Valenzano Menada M; Rundle S; Leone Roberti Maggiore U; Ferrero S
    Expert Opin Biol Ther; 2016; 16(3):407-19. PubMed ID: 26796332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
    Vergote I; Ray-Coquard I; Lorusso D; Oaknin A; Cibula D; Van Gorp T
    Expert Opin Investig Drugs; 2023 Mar; 32(3):201-211. PubMed ID: 36803278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
    Bose CK
    Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
    McNamara B; Chang Y; Mutlu L; Harold J; Santin AD
    Expert Opin Biol Ther; 2023 Mar; 23(3):227-233. PubMed ID: 36800548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab for advanced cervical cancer: safety and efficacy.
    De Felice F; Giudice E; Bolomini G; Distefano MG; Scambia G; Fagotti A; Marchetti C
    Expert Rev Anticancer Ther; 2021 Feb; 21(2):221-228. PubMed ID: 33183120
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
    O'Malley DM; Oaknin A; Monk BJ; Selle F; Rojas C; Gladieff L; Berton D; Leary A; Moore KN; Estevez-Diz MDP; Hardy-Bessard AC; Alexandre J; Opperman CP; de Azevedo CRAS; Randall LM; Feliu WO; Ancukiewicz M; Ray-Coquard I
    Gynecol Oncol; 2021 Nov; 163(2):274-280. PubMed ID: 34452745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer.
    García E; Ayoub N; Tewari KS
    J Gynecol Oncol; 2024 Jan; 35(1):e30. PubMed ID: 38072400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
    Peng H; He X; Wang Q
    Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for recurrent cervical cancer.
    Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
    Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer.
    Wolford JE; Tewari KS
    Expert Opin Drug Discov; 2018 May; 13(5):445-457. PubMed ID: 29463131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
    Wang R; Zhang Y; Shan F
    Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving standards and future directions for systemic therapies in cervical cancer.
    Ang DJM; Chan JJ
    J Gynecol Oncol; 2024 Mar; 35(2):e65. PubMed ID: 38282261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.
    McLachlan J; Boussios S; Okines A; Glaessgen D; Bodlar S; Kalaitzaki R; Taylor A; Lalondrelle S; Gore M; Kaye S; Banerjee S
    Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):153-160. PubMed ID: 27838135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
    Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
    Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.
    Monk BJ; Enomoto T; Kast WM; McCormack M; Tan DSP; Wu X; González-Martín A
    Cancer Treat Rev; 2022 May; 106():102385. PubMed ID: 35413489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.